AMRX
Price
$12.15
Change
+$0.20 (+1.67%)
Updated
Nov 24 closing price
Capitalization
3.82B
99 days until earnings call
Intraday BUY SELL Signals
VTRS
Price
$10.66
Change
+$0.09 (+0.85%)
Updated
Nov 25, 10:50 AM (EDT)
Capitalization
12.19B
97 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

AMRX vs VTRS

Header iconAMRX vs VTRS Comparison
Open Charts AMRX vs VTRSBanner chart's image
Amneal Pharmaceuticals
Price$12.15
Change+$0.20 (+1.67%)
Volume$2.58M
Capitalization3.82B
Viatris
Price$10.66
Change+$0.09 (+0.85%)
Volume$2.25K
Capitalization12.19B
AMRX vs VTRS Comparison Chart in %
AMRX
Daily Signal:
Gain/Loss:
VTRS
Daily Signal:
Gain/Loss:
View a ticker or compare two or three
VS
AMRX vs. VTRS commentary
Nov 25, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is AMRX is a StrongBuy and VTRS is a StrongBuy.

Interact to see
Advertisement
COMPARISON
Comparison
Nov 25, 2025
Stock price -- (AMRX: $12.15 vs. VTRS: $10.58)
Brand notoriety: AMRX and VTRS are both not notable
Both companies represent the Pharmaceuticals: Generic industry
Current volume relative to the 65-day Moving Average: AMRX: 150% vs. VTRS: 120%
Market capitalization -- AMRX: $3.82B vs. VTRS: $12.19B
AMRX [@Pharmaceuticals: Generic] is valued at $3.82B. VTRS’s [@Pharmaceuticals: Generic] market capitalization is $12.19B. The market cap for tickers in the [@Pharmaceuticals: Generic] industry ranges from $63.66B to $0. The average market capitalization across the [@Pharmaceuticals: Generic] industry is $4.11B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

AMRX’s FA Score shows that 1 FA rating(s) are green whileVTRS’s FA Score has 2 green FA rating(s).

  • AMRX’s FA Score: 1 green, 4 red.
  • VTRS’s FA Score: 2 green, 3 red.
According to our system of comparison, AMRX is a better buy in the long-term than VTRS.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

AMRX’s TA Score shows that 4 TA indicator(s) are bullish while VTRS’s TA Score has 5 bullish TA indicator(s).

  • AMRX’s TA Score: 4 bullish, 4 bearish.
  • VTRS’s TA Score: 5 bullish, 5 bearish.
According to our system of comparison, both AMRX and VTRS are a good buy in the short-term.

Price Growth

AMRX (@Pharmaceuticals: Generic) experienced а +4.92% price change this week, while VTRS (@Pharmaceuticals: Generic) price change was +0.40% for the same time period.

The average weekly price growth across all stocks in the @Pharmaceuticals: Generic industry was +3.14%. For the same industry, the average monthly price growth was -6.34%, and the average quarterly price growth was +15.31%.

Reported Earning Dates

AMRX is expected to report earnings on Mar 04, 2026.

VTRS is expected to report earnings on Mar 02, 2026.

Industries' Descriptions

@Pharmaceuticals: Generic (+3.14% weekly)

A generic drug contains the same chemical substance as a drug that was originally protected by patents. Generic drugs are generally sold at cheaper price points, compared to name-brand pharmaceuticals, after patents for the more expensive drugs lapse. The generic drug industry has created a major market, thanks to the lower pricing. According to the Center for Justice and Democracy at New York Law School, 80 percent of all drugs prescribed are generic, and generic drugs are chosen 94 percent of the time when they are available. But their manufacturers must be able to prove to the FDA that they can be effective substitutes for the original drugs. Some of the major generic drug makers include Zoetis, Inc., Allergan plc and Mylan N.V.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
VTRS($12.2B) has a higher market cap than AMRX($3.82B). AMRX has higher P/E ratio than VTRS: AMRX (1195.00) vs VTRS (236.20). AMRX YTD gains are higher at: 53.409 vs. VTRS (-10.703). AMRX has higher annual earnings (EBITDA): 584M vs. VTRS (-598.9M). VTRS has more cash in the bank: 406M vs. AMRX (71.5M). AMRX has less debt than VTRS: AMRX (2.58B) vs VTRS (14.8B). VTRS has higher revenues than AMRX: VTRS (14.1B) vs AMRX (2.85B).
AMRXVTRSAMRX / VTRS
Capitalization3.82B12.2B31%
EBITDA584M-598.9M-98%
Gain YTD53.409-10.703-499%
P/E Ratio1195.00236.20506%
Revenue2.85B14.1B20%
Total Cash71.5M406M18%
Total Debt2.58B14.8B17%
FUNDAMENTALS RATINGS
AMRX vs VTRS: Fundamental Ratings
AMRX
VTRS
OUTLOOK RATING
1..100
8581
VALUATION
overvalued / fair valued / undervalued
1..100
100
Overvalued
8
Undervalued
PROFIT vs RISK RATING
1..100
37100
SMR RATING
1..100
9896
PRICE GROWTH RATING
1..100
3852
P/E GROWTH RATING
1..100
121
SEASONALITY SCORE
1..100
5050

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

VTRS's Valuation (8) in the null industry is significantly better than the same rating for AMRX (100) in the Pharmaceuticals Major industry. This means that VTRS’s stock grew significantly faster than AMRX’s over the last 12 months.

AMRX's Profit vs Risk Rating (37) in the Pharmaceuticals Major industry is somewhat better than the same rating for VTRS (100) in the null industry. This means that AMRX’s stock grew somewhat faster than VTRS’s over the last 12 months.

VTRS's SMR Rating (96) in the null industry is in the same range as AMRX (98) in the Pharmaceuticals Major industry. This means that VTRS’s stock grew similarly to AMRX’s over the last 12 months.

AMRX's Price Growth Rating (38) in the Pharmaceuticals Major industry is in the same range as VTRS (52) in the null industry. This means that AMRX’s stock grew similarly to VTRS’s over the last 12 months.

VTRS's P/E Growth Rating (1) in the null industry is in the same range as AMRX (12) in the Pharmaceuticals Major industry. This means that VTRS’s stock grew similarly to AMRX’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
AMRXVTRS
RSI
ODDS (%)
Bearish Trend 1 day ago
89%
Bearish Trend 1 day ago
83%
Stochastic
ODDS (%)
Bearish Trend 1 day ago
71%
Bearish Trend 1 day ago
67%
Momentum
ODDS (%)
Bullish Trend 1 day ago
85%
Bullish Trend 1 day ago
69%
MACD
ODDS (%)
Bullish Trend 1 day ago
90%
Bearish Trend 1 day ago
75%
TrendWeek
ODDS (%)
Bullish Trend 1 day ago
81%
Bullish Trend 1 day ago
64%
TrendMonth
ODDS (%)
Bullish Trend 1 day ago
80%
Bullish Trend 1 day ago
59%
Advances
ODDS (%)
Bullish Trend 1 day ago
81%
Bullish Trend 1 day ago
69%
Declines
ODDS (%)
Bearish Trend 7 days ago
73%
Bearish Trend 6 days ago
66%
BollingerBands
ODDS (%)
Bearish Trend 1 day ago
85%
Bearish Trend 1 day ago
65%
Aroon
ODDS (%)
Bullish Trend 1 day ago
79%
Bullish Trend 1 day ago
65%
View a ticker or compare two or three
Interact to see
Advertisement
AMRX
Daily Signal:
Gain/Loss:
VTRS
Daily Signal:
Gain/Loss:
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
CZMGX20.620.48
+2.38%
Multi-Manager Growth Strategies Inst
WFGGX30.87N/A
N/A
First Trust WCM Focused Global Gr Inv
TGWRX14.29N/A
N/A
Transamerica Large Growth R
VGHCX206.36N/A
N/A
Vanguard Health Care Inv
AFEDX57.55N/A
N/A
American Century Large Cap Equity R6

AMRX and

Correlation & Price change

A.I.dvisor indicates that over the last year, AMRX has been loosely correlated with VTRS. These tickers have moved in lockstep 47% of the time. This A.I.-generated data suggests there is some statistical probability that if AMRX jumps, then VTRS could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To AMRX
1D Price
Change %
AMRX100%
+1.67%
VTRS - AMRX
47%
Loosely correlated
+2.32%
TEVA - AMRX
42%
Loosely correlated
+2.31%
AMPH - AMRX
42%
Loosely correlated
+2.69%
PAHC - AMRX
41%
Loosely correlated
+3.39%
BHC - AMRX
39%
Loosely correlated
+1.33%
More

VTRS and

Correlation & Price change

A.I.dvisor indicates that over the last year, VTRS has been loosely correlated with ELAN. These tickers have moved in lockstep 49% of the time. This A.I.-generated data suggests there is some statistical probability that if VTRS jumps, then ELAN could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To VTRS
1D Price
Change %
VTRS100%
+2.32%
ELAN - VTRS
49%
Loosely correlated
+3.78%
AMPH - VTRS
48%
Loosely correlated
+2.69%
AMRX - VTRS
47%
Loosely correlated
+1.67%
ZTS - VTRS
40%
Loosely correlated
+0.66%
ALKS - VTRS
37%
Loosely correlated
-1.43%
More